We observed there was a graft versus host disease in the GIFT4-treated NSG mice but not in PBS- or GM-CSF and IL-4 treated groups, due to the cytotoxicity of GIFT4-CLL cell-primed human T cells. Here, IL4 is linked to B-cell chronic lymphocytic leukemia.